Use

This germline test targets BRCA2, a high‑penetrance gene associated with hereditary breast and ovarian cancer risk. Identification of pathogenic variants in BRCA2 can inform patient and familial cancer risk, guide surveillance, and influence treatment decisions, including eligibility for PARP inhibitor therapy.